CA
JAZZ icon

Centerpoint Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Centerpoint Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11
Closed -$2K – 263
2019
Q4 		$2K Hold
11
– – ﹤0.01% 251
2019
Q3 		$1K Hold
11
– – ﹤0.01% 259
2019
Q2 		$2K Hold
11
– – ﹤0.01% 239
2019
Q1 		$2K Hold
11
– – ﹤0.01% 230
2018
Q4 		$1K Hold
11
– – ﹤0.01% 239
2018
Q3 		$2K Hold
11
– – ﹤0.01% 216
2018
Q2 		$2K Buy
+11
New +$1.8K ﹤0.01% 308

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Centerpoint Advisors's JAZZ Position: Q1 2020 in Review

Centerpoint Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 11 shares — an estimated $2K sold.

Centerpoint Advisors first reported a position in JAZZ in Q2 2018 and held it in 7 quarters. The position peaked at $2K in Q4 2019. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

  • Centerpoint Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Centerpoint Advisors sold 11 Jazz Pharmaceuticals shares in Q1 2020, an estimated $2K.
  • Centerpoint Advisors first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 7 quarters.
  • Centerpoint Advisors's Jazz Pharmaceuticals position peaked at $2K in Q4 2019.
  • 407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Centerpoint Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.